VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

VistaGen Therapeutics reports Q1 loss, focuses on FDA approval

VistaGen Therapeutics faces financial challenges with increased expenses but shows strength in its innovative drug candidates targeting mental health disorders. The company's opportunities lie in FDA approval for fasedienol and market expansion for its pherine drug candidates.

VistaGen reports positive trial results and financial stability in Q2

VistaGen Therapeutics showcased positive trial results and financial stability, emphasizing the potential of their pherine pipeline to create value and improve lives.
While facing challenges such as increased expenses and operational concerns, the company's commitment to advancing treatments presents opportunities for growth and market expansion.
Analyst interest in study details and timelines reflects investor confidence in VistaGen's research programs and potential market impact.
Overall, VistaGen's Q2 performance highlights progress in lead programs and a solid financial foundation for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline

VistaGen Therapeutics' (VTGN) CEO Shawn Singh on Q2 2022 Results - Earnings Call Transcript

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates

PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan

VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update

Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know

VistaGen VTGN +0.4% (Get Free Alerts for VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous systems (“CNS”) disorders, today announced the initiation of a phase 2A clinical trial to evaluate the efficacy, safety, and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety (“AjDA”).

VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial

Study Launches Phase 2A Clinical Program Designed to Explore PH94B's Potential in Multiple Additional Anxiety Disorders

VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder

Preclinical study of intranasal radiolabeled PH94B in laboratory rats further differentiates PH94B's mechanism of action from benzodiazepines Preclinical study of intranasal radiolabeled PH94B in laboratory rats further differentiates PH94B's mechanism of action from benzodiazepines

VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B's Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain

PALISADE Phase 3 Program focused on PH94B's potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder PALISADE Phase 3 Program focused on PH94B's potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder

VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 20.00% and -4.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q1 2022 Results - Earnings Call Transcript

Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the past year to ($0.04), which beat the estimate of ($0.05).

Recap: VistaGen Therapeutics Q1 Earnings

PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan

VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in the Canaccord Genuity 41st Annual Growth Conference including a fireside chat with Shawn Singh, Chief Executive Officer, on Wednesday, August 11 at 1:30 p.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.

VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in the ‘Updates in Neuropsych' panel at the virtual William Blair Biotech Focus Conference 2021 on July 15, 2021 at 9:00 a.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.

VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021

Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders

VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors

Gran Tierra Energy

IAMGOLD

Meten Holding Group Ltd.

McEwen Mining

Pieris Pharma

Sesen Bio Inc.

Uranium Energy

Making a penny stocks watchlist for 2021? Check these 8 out The post Are These 8 Penny Stocks to Watch on Your List Right Now?

Are These 8 Penny Stocks to Watch on Your List Right Now?

Investors liked the drugmaker's corporate update.

Why VistaGen Therapeutics Stock Jumped Today

VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2021 Results - Earnings Call Transcript

Shares of VistaGen Therapeutics (NASDAQ:VTGN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 328.57% over the past year to ($0.30), which missed the estimate of ($0.05).

VistaGen Therapeutics: Q4 Earnings Insights

PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD)

VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update

Sphere 3D

Catalyst Biosciences

Iterum Therapeutics Plc

GEE Group

SeaChange International

Electrameccanica

Vislink Technologies Inc

Which penny stocks are investors watching as June comes to an end? The post 8 Penny Stocks to Watch Right Now As June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Penny Stocks to Watch Right Now As June Comes to an End

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will host a corporate update conference call on Tuesday, June 29, 2021 at 2:00 pm Pacific Time (5:00 pm Eastern Time) to discuss its financial and operating results for its fiscal year ended March 31, 2021 and provide a business update.

VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the Company will be added to the Russell 2000® Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opens on Monday, June 28, 2021, according to a preliminary list of additions posted on June 4, 2021.

VistaGen Therapeutics Set to Join the Russell 2000® Index

Bionano Genomics

BioNTech SE

Avid Bioservices

Moderna

BioCryst Pharmaceuticals

22nd Century Group

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.

News for VistaGen Therapeutics Stock (VTGN)